Six-year experience with a comprehensive approach to the treatment of recurrent childhood acute lymphoblastic leukemia (ALL-REZ BFM 85). A relapse study of the BFM group.

Between April 1985 and March 1987 130 children and adolescents up to 18 years of age with first relapse of acute lymphoblastic leukemia (ALL) were registered on the stratified and randomized multicentric trial ALL-REZ BFM 85 designed for patients pretreated with intensive front-line therapies. Stratification criteria were time and site of relapse: bone marrow (BM) relapse on or up to 6 months after stopping front-line therapy (group A), BM relapse beyond 6 months after therapy (group B), and isolated extramedullary relapse at any time (group C). Treatment consisted of alternating courses of polychemotherapy including randomly administered high- or intermediate-dose methotrexate (HDMTX:12 g/m2 as 4-hour infusion; IDMTX: 1 g/m2 as 36-hour infusion). During maintenance therapy the patients received daily oral thioguanine and biweekly intravenous (IV) MTX. The overall second complete remission (CR) rate was 92% (groups A, B, and C: 88%, 92%, and 100%), and the probability of event-free survival (EFS) at 6 years is 0.31 +/- 0.04 (groups A, B, and C: 0.18 +/- 0.05, 0.30 +/- 0.07, and 0.72 +/- 0.11). HDMTX did not prove to be superior to IDMTX, which led to premature stopping of randomization. Risk factor analyses showed early relapse, particularly BM relapse within 18 months, and T-cell phenotype to be independent predictors of poor outcome. The incidence of central nervous system (CNS) relapses following BM relapse was 19%, indicating that reprophylaxis to the CNS with IV/intrathecal (IT) MTX was insufficient. For 17 children who received bone marrow transplantation in second CR from HLA-compatible siblings the EFS was 0.53 +/- 0.12 at 5 years. Their outcome was not influenced by the above-mentioned risk factors. With the proposed treatment regimen long-lasting second remissions can be achieved in about one third of patients even after intensive front-line treatment.

[1]  G. Henze,et al.  Results and significance of six randomized trials in four consecutive ALL-BFM studies. , 1990 .

[2]  J. Hermans,et al.  The significance of an isolated central nervous system relapse, occurring as first relapse in children with acute lymphoblastic leukemia , 1989, Cancer.

[3]  W. Hiddemann,et al.  Ambiguous phenotypes and genotypes in 16 children with acute leukemia as characterized by multiparameter analysis. , 1988, Blood.

[4]  C. Pui,et al.  Cyclic combination chemotherapy for acute lymphoblastic leukemia recurring after elective cessation of therapy. , 1988, Medical and pediatric oncology.

[5]  S. George,et al.  Second central nervous system prophylaxis in children with acute lymphoblastic leukemia who relapse after elective cessation of therapy. , 1983, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  E. Thomas,et al.  Marrow transplantation for children with acute lymphoblastic leukemia in second remission. , 1987, Blood.

[7]  R. Bender,et al.  Membrane transport of methotrexate in human lymphoblastoid cells. , 1978, Cancer research.

[8]  J. Belasco,et al.  Multiagent chemotherapy in relapsed acute lymphoblastic leukemia in children , 1990, Cancer.

[9]  J. Schornagel,et al.  Cytotoxicity of methotrexate and trimetrexate and its reversal by folinic acid in human leukemic CCRF-CEM cells with carrier-mediated and receptor-mediated folate uptake. , 1989, Leukemia research.

[10]  R. Gale,et al.  WHICH TREATMENT FOR CHILDHOOD ACUTE LYMPHOBLASTIC LEUKAEMIA IN SECOND REMISSION? , 1987, The Lancet.

[11]  G. Henze,et al.  Risk of CNS relapse after systemic relapse of childhood acute lymphoblastic leukemia. , 1990, Haematology and blood transfusion.

[12]  G. Rivera,et al.  Reinduction therapy in 297 children with acute lymphoblastic leukemia in first bone marrow relapse: a Pediatric Oncology Group Study. , 1988, Blood.

[13]  S. Srimatkandada,et al.  Methotrexate resistant cells as targets for selective chemotherapy. , 1985, Advances in enzyme regulation.

[14]  G. Henze,et al.  Treatment strategy for different risk groups in childhood acute lymphoblastic leukemia: A Report From the BFM Study Group. , 1981, Haematology and blood transfusion.

[15]  F. Lampert,et al.  Acute Lymphoblastic Leukaemia , 1986 .

[16]  P. Steinherz,et al.  Reinduction therapy for advanced or refractory acute lymphoblastic leukemia of childhood , 1989, Cancer.

[17]  R. Levinsky,et al.  BONE-MARROW TRANSPLANTATION HAS A LIMITED ROLE IN PROLONGING SECOND MARROW REMISSION IN CHILDHOOD LYMPHOBLASTIC LEUKAEMIA , 1986, The Lancet.

[18]  F. Behm,et al.  Improved outcome in childhood acute lymphoblastic leukaemia with reinforced early treatment and rotational combination chemotherapy , 1991, The Lancet.

[19]  S L George,et al.  Clinical pharmacodynamics of high-dose methotrexate in acute lymphocytic leukemia. Identification of a relation between concentration and effect. , 1986, The New England journal of medicine.

[20]  R. Gelber,et al.  Four-agent induction and intensive asparaginase therapy for treatment of childhood acute lymphoblastic leukemia. , 1986, The New England journal of medicine.

[21]  D. Rogers,et al.  Outcome following late marrow relapse in childhood acute lymphoblastic leukemia. , 1984, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.